Qilian International Holding Group Limited (QLI)
After hours:
| Previous close | 0.7580 |
| Open | 0.7546 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.5500 - 0.7626 |
| 52-week range | 0.3550 - 1.0440 |
| Volume | |
| Avg. volume | 183,211 |
| Market cap | 20.739M |
| Beta (5Y monthly) | 1.43 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.2200 |
| Earnings date | 21 May 2024 - 22 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 27 Feb 2023 |
| 1y target est | N/A |
PR NewswireQilian International plans to adjust industrial investment
Qilian International Holdings Group Limited (NASDAQ: QLI) ("Qilian" or the "Company"), a pharmaceutical and chemical products manufacturer headquartered in China, today announced: In the past two years, Qilian International Holdings Group Limited has encountered significant challenges stemming from the continuous shrinkage in market demand for its oxytetracycline products, coupled with a persistent decline in market prices and escalating environmental protection standards. These factors have col
PR NewswireQilian International Holding Group Receives 180-day Extension from Nasdaq to Meet Minimum Bid Price Rule
Qilian International Holding Group Limited (NASDAQ: QLI) ("Qilian" or the "Company"), a China-based pharmaceutical and chemical products manufacturer, today announced that on January 10, 2024, the Company received a written notification from the Nasdaq's Listing Qualifications Department, granting the Company another 180 calendar days extension, or until July 8, 2024, to regain compliance with Nasdaq's minimum bid price requirement.
Simply Wall St.Qilian International Holding Group First Half 2023 Earnings: EPS: US$0.014 (vs US$0.002 in 1H 2022)
Qilian International Holding Group ( NASDAQ:QLI ) First Half 2023 Results Key Financial Results Revenue: US$29.2m (down...
